Fox Chase Chemical Diversity Center, Inc
Publicly observedDoylestown, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Doylestown | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Fox Chase Chemical Diversity Center, Inc | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | V6EQM9ABEM89 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant19 Apr 2021Publicly observed
NIH SBIR/STTR award: Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum
USD 964,562.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant19 Apr 2021Publicly observed
NIH SBIR/STTR award: Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum
USD 967,415.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant20 Jul 2020Publicly observed
NIH SBIR/STTR award: Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle
USD 1,000,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.